Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple
sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 …

Objective This study was undertaken to assess the impact of immunosuppressive and
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in people …

We evaluated the effect of DMTs on Covid‐19 severity in patients with MS, with a pooled‐analysis
of two large cohorts from Italy and France. The association of baseline characteristics …

… Severe thrombophilia was defined as the presence of antithrombin, protein C or protein S
deficiency, antiphospholipid antibodies and by the concomitant presence of more than one …

We assembled and analyzed genetic data of 47,351 multiple sclerosis (MS) subjects and
68,284 control subjects and establish a reference map of the genetic architecture of MS that …

Objective A proportion of multiple sclerosis (MS) patients experience disease activity
despite treatment. The early identification of the most effective drug is critical to impact long‐term …

We have read with interest the recent paper published in this journal by Maghzi et al.[1]
reporting a case series of five teriflunomide-treated multiple sclerosis (MS) patients who …

Background: Little is known about COVID-19 course and outcomes after a third booster
dose of mRNA vaccine against SARS-CoV-2 (mRNA-Vax) in patients with multiple sclerosis (…

Background: The role of genetic factors in influencing the clinical expression of multiple
sclerosis (MS) is unclear. Objective: The objective of this paper is to identify genes, pathways …

Background and purpose Clinical outcomes of multiple sclerosis (MS) patients affected by
coronavirus disease 2019 (COVID‐19) have been thoroughly investigated, but a further …